Brandon Coder
YOU?
Author Swipe
View article: Supplementary Figure 8 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 8 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 8. Study design for Part A and Part D.
View article: Supplementary Table 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Table 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Table 2. Safety summary for patients who received a dose of mRNA-4157.
View article: Supplementary Figure 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 2 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 2. Characterization of mRNA-4157 neoantigen pool-specific T cells post-expansion at pre-treatment and post-treatment for patients who received mRNA-4157 monotherapy (A–C) or combination therapy (D–K). (L) Alluvial plot…
View article: Supplementary Figure 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 4. Predicted HLA alleles (A) and their associated immunogenic epitopes (B) in patients treated with mRNA-4157 monotherapy.
View article: Supplementary Figure 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 1. Disease status of patients in the study compared with those of broader melanoma populations.
View article: Peptide list and HLA types from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Peptide list and HLA types from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Peptide list and HLA types.
View article: Supplementary Figure 5 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 5 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 5. Predicted HLA alleles (A) and their associated immunogenic epitopes (B) in patients treated with combination therapy.
View article: Supplementary Table 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Table 1 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Table 1. Representativeness of study participants.
View article: Supplementary Figure 7 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 7 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 7. Distribution of T cell subsets pre-treatment and post-treatment for high (Patients 7 and 6) and low (Patients 13 and 14) immune responders.
View article: Supplementary Table 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Table 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Table 3. Cellular markers used for post-expansion intracellular staining and identification of CD4 and CD8 responses.
View article: Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 3. Patient responses to individual neoantigens at pre-treatment and post-treatment for patients who received mRNA-4157 monotherapy (A–C) or combination therapy (D–J) using ELISpot assay.
View article: Supplementary Figure 6 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Figure 6 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Figure 6. mRNA-4157 in combination with pembrolizumab activates an adaptive immune response.
View article: Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary Table 4. Cellular markers used for ex vivo immune phenotyping.
View article: Supplementary methods from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Supplementary methods from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
Supplementary methods.
View article: Data from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study
Data from T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study Open
mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens to induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of mRNA-415…
View article: 1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab
1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab Open
Background The identification of cancer-specific T cell receptor (TCR) sequences is paramount to the advancement of cancer immunotherapies. Recent studies and clinical trials have shown that monoclonal T cell therapy is prone to immune eva…
View article: Supplemental Material and Methods from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Supplemental Material and Methods from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
File contains the supplementary Material and Methods
View article: Figure S1 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Figure S1 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
CCR8 mAb treatment mediates potent antitumor activity, suppressing MC38 tumor growth and improving long-term survival.
View article: Figure S2 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Figure S2 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
The frequency of peripheral Tregs in tumor-bearing αCCR8-treated mice and the effects of αCCR8 on ex vivo tumor CD8+ and CD4+ T cells.
View article: Figure S3 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Figure S3 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
Expression of Lm-AH1 vaccine construct.
View article: Figure S2 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Figure S2 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
The frequency of peripheral Tregs in tumor-bearing αCCR8-treated mice and the effects of αCCR8 on ex vivo tumor CD8+ and CD4+ T cells.
View article: Figure S1 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Figure S1 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
CCR8 mAb treatment mediates potent antitumor activity, suppressing MC38 tumor growth and improving long-term survival.
View article: Figure S3 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Figure S3 from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
Expression of Lm-AH1 vaccine construct.
View article: Data from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Data from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
CCR8 is a chemokine receptor expressed principally on regulatory T cells (Treg) and is known to be critical for CCR8+ Treg-mediated immunosuppression. Recent studies have demonstrated that CCR8 is uniquely upregulated in human tumor-reside…
View article: Data from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Data from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
CCR8 is a chemokine receptor expressed principally on regulatory T cells (Treg) and is known to be critical for CCR8+ Treg-mediated immunosuppression. Recent studies have demonstrated that CCR8 is uniquely upregulated in human tumor-reside…
View article: Supplemental Material and Methods from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer
Supplemental Material and Methods from Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer Open
File contains the supplementary Material and Methods
View article: <i>Listeria monocytogenes</i>personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens
<i>Listeria monocytogenes</i>personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens Open
Background Recent advances in the field of cancer immunotherapy have identified CD8 + T cell responses against tumor-specific mutations as a key driver of tumor regression and overall survival. ADXS-NEO is a personalized Listeria monocytog…
View article: Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging
Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging Open
The interaction between T cells and the central nervous system (CNS) in homeostasis and injury has been recognized being both pathogenic (CD4+ T-helper 1 - Th1, Th17 and γδT) and ameliorative (Th2 and regulatory T cells - Tregs). However, …
View article: Thymic involution beyond T-cell insufficiency
Thymic involution beyond T-cell insufficiency Open
It is well known that age-related involution (shrinkage) of the thymus (a central cellular immune organ) results in decreased output of naive T cells [1]. The insufficiency of naive T cells significantly reduces the T cell receptor reperto…
View article: Thymic Involution Perturbs Negative Selection Leading to Autoreactive T Cells That Induce Chronic Inflammation
Thymic Involution Perturbs Negative Selection Leading to Autoreactive T Cells That Induce Chronic Inflammation Open
Thymic involution and the subsequent amplified release of autoreactive T cells increase the susceptibility toward developing autoimmunity, but whether they induce chronic inflammation with advanced age remains unclear. The presence of chro…